Associated Papers
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.
Nousias O et al.
Lung Cancer (amsterdam, Netherlands), 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.
Chan SWS et al.
Clinical Lung Cancer, 2025
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.
Zapata Dongo RJ et al.
Frontiers in Pharmacology, 2025
Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors.
Gu J et al.
Frontiers in Pharmacology, 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
Ek T et al.
Cancer Research Communications, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J et al.
Cancer Communications (london, England), 2024
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X et al.
Computers in Biology and Medicine, 2024
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR et al.
Nature Genetics, 2024
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Yoshida T et al.
Cancer Science, 2023
Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report.
Saw SPL et al.
Jto Clinical and Research Reports, 2023
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.
Kiełbowski K et al.
Frontiers in Pharmacology, 2023
ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib.
Guan J et al.
Frontiers in Oncology, 2023
Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
Wu H et al.
Bmc Cancer, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA et al.
Lung Cancer (amsterdam, Netherlands), 2022
Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.
Hu H et al.
Translational Cancer Research, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A et al.
Nature Cancer, 2022
Clinical and genomic features of Chinese lung cancer patients with germline mutations.
Peng W et al.
Nature Communications, 2022
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
Hua G et al.
Esmo Open, 2022
One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
Lee Y et al.
The Oncologist, 2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT et al.
European Journal of Cancer (oxford, England : 1990), 2021
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
Yang Y et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review).
Wang L et al.
Oncology Reports, 2021
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
Zhu VW et al.
Jto Clinical and Research Reports, 2021
Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report.
Yao B et al.
Oncotargets and Therapy, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition.
Urbanska EM et al.
International Journal of Molecular Sciences, 2020
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K et al.
Thoracic Cancer, 2020
Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055).
Li M et al.
Frontiers in Oncology, 2020
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.
Dagogo-Jack I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics.
Chan HT et al.
Oncology and Therapy, 2019
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2019
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
Ding M et al.
Clinical Lung Cancer, 2019
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K et al.
Ebiomedicine, 2019
Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T et al.
Respiratory Investigation, 2019
Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data.
Patterson SE et al.
Npj Precision Oncology, 2019
Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.
Johnson TW et al.
Acs Medicinal Chemistry Letters, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J et al.
Thoracic Cancer, 2018
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
McCoach CE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Yoda S et al.
Cancer Discovery, 2018
Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Xu Y et al.
Cancer Communications (london, England), 2018
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Addeo A et al.
Critical Reviews in Oncology/hematology, 2018